{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:46:28Z","timestamp":1790401588411,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1053\/j.ajkd.2009.11.013","type":"journal-article","created":{"date-parts":[[2010,1,30]],"date-time":"2010-01-30T04:27:36Z","timestamp":1264825656000},"page":"835-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":180,"title":["Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis"],"prefix":"10.1053","volume":"55","author":[{"given":"Pantelis A.","family":"Sarafidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis C.","family":"Stafylas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis I.","family":"Georgianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios N.","family":"Saratzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios N.","family":"Lasaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"issue":"1(suppl 1)","key":"10.1053\/j.ajkd.2009.11.013_bib2","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1053\/j.ajkd.2006.11.019","article-title":"Excerpts from the United States Renal Data System 2006 Annual Data Report","volume":"49","author":"Collins","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2009.11.013_bib3","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1523-1755.2005.00227.x","article-title":"Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000)","volume":"67","author":"Van Dijk","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.11.013_bib4","series-title":"ERA-EDTA Registry 2004 Annual Report","year":"2006"},{"issue":"5(suppl 2)","key":"10.1053\/j.ajkd.2009.11.013_bib5","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1(suppl 1)","key":"10.1053\/j.ajkd.2009.11.013_bib6","first-page":"S4","article-title":"Standards of medical care in diabetes\u20142007","volume":"30","year":"2007","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1053\/j.ajkd.2009.11.013_bib7","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2009.11.013_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1472-8206.2008.00568.x","article-title":"Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update","volume":"22","author":"Sarafidis","year":"2008","journal-title":"Fundam Clin Pharmacol"},{"issue":"8","key":"10.1053\/j.ajkd.2009.11.013_bib9","first-page":"1326","article-title":"Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats","volume":"47","author":"Buckingham","year":"1998","journal-title":"Diabetes"},{"issue":"6","key":"10.1053\/j.ajkd.2009.11.013_bib10","first-page":"989","article-title":"Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats","volume":"272","author":"Yoshimoto","year":"1997","journal-title":"Am J Physiol"},{"issue":"7","key":"10.1053\/j.ajkd.2009.11.013_bib11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.ki.5001620","article-title":"Protection of the kidney by thiazolidinediones: an assessment from bench to bedside","volume":"70","author":"Sarafidis","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2009.11.013_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1056-8727(00)00124-0","article-title":"Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients","volume":"14","author":"Nakamura","year":"2000","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.jhh.1001444","article-title":"Rosiglitazone reduces urinary albumin excretion in type II diabetes","volume":"17","author":"Bakris","year":"2003","journal-title":"J Hum Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00416.x","article-title":"A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2009.11.013_bib15","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.0 [updated February 2008]","year":"2008"},{"issue":"4","key":"10.1053\/j.ajkd.2009.11.013_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"7109","key":"10.1053\/j.ajkd.2009.11.013_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"9193","key":"10.1053\/j.ajkd.2009.11.013_bib18","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1053\/j.ajkd.2009.11.013_bib20","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diabetes.54.7.2206","article-title":"Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients","volume":"54","author":"Pistrosch","year":"2005","journal-title":"Diabetes"},{"issue":"10","key":"10.1053\/j.ajkd.2009.11.013_bib21","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1097\/01.hjh.0000244955.39491.88","article-title":"Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria","volume":"24","author":"Bakris","year":"2006","journal-title":"J Hypertens"},{"issue":"9","key":"10.1053\/j.ajkd.2009.11.013_bib22","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.clinthera.2007.09.011","volume":"29","author":"Davidson","year":"2007","journal-title":"Clin Ther"},{"issue":"11","key":"10.1053\/j.ajkd.2009.11.013_bib23","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.ki.5002516","article-title":"Rosiglitazone decreases albuminuria in type 2 diabetic patients","volume":"72","author":"Miyazaki","year":"2007","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2009.11.013_bib24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/meta.2001.26703","article-title":"Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria","volume":"50","author":"Nakamura","year":"2001","journal-title":"Metabolism"},{"issue":"4","key":"10.1053\/j.ajkd.2009.11.013_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.amjmed.2003.07.023","article-title":"Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial","volume":"116","author":"Aljabri","year":"2004","journal-title":"Am J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2337\/diacare.27.1.141","article-title":"One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes","volume":"27","author":"Hanefeld","year":"2004","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1053\/j.ajkd.2009.11.013_bib27","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.metabol.2004.05.013","article-title":"Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients","volume":"53","author":"Nakamura","year":"2004","journal-title":"Metabolism"},{"issue":"12","key":"10.1053\/j.ajkd.2009.11.013_bib28","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","article-title":"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial","volume":"89","author":"Schernthaner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.ajkd.2009.11.013_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.metabol.2003.10.025","article-title":"Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes","volume":"53","author":"Yanagawa","year":"2004","journal-title":"Metabolism"},{"issue":"2","key":"10.1053\/j.ajkd.2009.11.013_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/dmrr.478","article-title":"Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study","volume":"21","author":"Matthews","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1053\/j.ajkd.2009.11.013_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/dmrr.633","article-title":"Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria","volume":"22","author":"Nakamura","year":"2006","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1053\/j.ajkd.2009.11.013_bib32","first-page":"170","article-title":"Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy","volume":"89","author":"Katavetin","year":"2006","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"10.1053\/j.ajkd.2009.11.013_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000104089","article-title":"Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy","volume":"30","author":"Jin","year":"2007","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2009.11.013_bib35","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2337\/diabetes.54.7.2164","article-title":"The early natural history of nephropathy in type 1 diabetes: III","volume":"54","author":"Steinke","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"10.1053\/j.ajkd.2009.11.013_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy","volume":"45","author":"Atkins","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2009.11.013_bib37","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"De Zeeuw","year":"2004","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2009.11.013_bib38","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfl309","article-title":"Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease","volume":"21","author":"Sarafidis","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2009.11.013_bib39","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc07-1868","article-title":"Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial","volume":"31","author":"Dagenais","year":"2008","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2009.11.013_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.HYP.37.2.722","article-title":"Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells","volume":"37","author":"Nicholas","year":"2001","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2337\/diabetes.53.1.200","article-title":"Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells","volume":"53","author":"Guo","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1053\/j.ajkd.2009.11.013_bib42","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1681\/ASN.V132342","article-title":"Biphasic vasodilator action of troglitazone on the renal microcirculation","volume":"13","author":"Arima","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2009.11.013_bib43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1559-4572.2008.00009.x","article-title":"Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?","volume":"3","author":"Sarafidis","year":"2008","journal-title":"J Cardiometab Syndr"},{"issue":"9","key":"10.1053\/j.ajkd.2009.11.013_bib44","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1093\/ndt\/gfn157","article-title":"Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"23","author":"Ko","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2009.11.013_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1559-4564.2007.06666.x","article-title":"Insulin resistance and oxidant stress: an interrelation with deleterious renal consequences?","volume":"2","author":"Sarafidis","year":"2007","journal-title":"J Cardiometab Syndr"},{"issue":"3","key":"10.1053\/j.ajkd.2009.11.013_bib46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.ASN.0000050414.52908.DA","article-title":"PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway","volume":"14","author":"Ruan","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2009.11.013_bib47","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1523-1755.2000.00355.x","article-title":"Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis","volume":"58","author":"Rerolle","year":"2000","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.ajkd.2009.11.013_bib48","first-page":"1040","article-title":"Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats","volume":"117","author":"Dong","year":"2004","journal-title":"Chin Med J"},{"issue":"24","key":"10.1053\/j.ajkd.2009.11.013_bib49","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2009.11.013_bib50","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-147-8-200710160-00182","article-title":"Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death","volume":"147","author":"Diamond","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2009.11.013_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes\u2014an interim analysis","volume":"357","author":"Home","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2009.11.013_bib52","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2009.11.013_bib53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijcard.2008.06.005","article-title":"The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality","volume":"131","author":"Stafylas","year":"2009","journal-title":"Int J Cardiol"},{"issue":"9681","key":"10.1053\/j.ajkd.2009.11.013_bib54","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638609015832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638609015832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:54:04Z","timestamp":1759456444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638609015832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0272638609015832"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2009.11.013","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2009.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}